EG434729 Inhibitors
EG434729 inhibitors are a specialized class of chemical compounds designed to specifically target and inhibit the function of the EG434729 protein, which plays a critical role in cellular processes such as signal transduction, enzymatic regulation, and intracellular transport. EG434729 is likely involved in facilitating key interactions between different molecules within signaling pathways, helping regulate the flow of information and maintaining cellular homeostasis. Inhibitors of EG434729 function by binding to essential regions of the protein, such as its active site or regulatory domains, thereby preventing the protein from interacting with its natural substrates or other binding partners. This inhibition can occur through different mechanisms, including competitive binding, where the inhibitor directly competes with a natural ligand, or allosteric modulation, where the inhibitor binds at a separate site and induces conformational changes that hinder the protein's function. The key challenge in developing EG434729 inhibitors is achieving a high degree of specificity for this protein, ensuring that the inhibition does not affect other similar proteins in related pathways.
The design and development of EG434729 inhibitors require a detailed understanding of the protein's structure and function, obtained through various structural biology methods such as X-ray crystallography, cryo-electron microscopy (cryo-EM), and nuclear magnetic resonance (NMR) spectroscopy. These techniques provide high-resolution information about the three-dimensional architecture of EG434729, revealing potential binding pockets and interaction surfaces that are critical for its function. With this information, computational modeling tools such as molecular docking and molecular dynamics simulations can be employed to predict the binding interactions of potential inhibitors with the protein, allowing for optimization of their binding affinity and selectivity. The chemical structures of EG434729 inhibitors are often modified to include functional groups that facilitate specific interactions, such as hydrophobic regions for better contact within binding pockets, or polar groups to establish hydrogen bonds with key amino acid residues. Structure-activity relationship (SAR) studies are used extensively to refine these inhibitors, ensuring that changes to their structure enhance their inhibitory properties without compromising stability or solubility. EG434729 inhibitors can range from small organic molecules that precisely target active sites to larger, more complex molecules that engage multiple regions of the protein. These inhibitors are designed not only to effectively modulate the activity of EG434729 but also to provide valuable insights into the protein's role in cellular signaling and regulatory networks.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Deferoxamine | 70-51-9 | sc-507390 | 5 mg | $250.00 | ||
Iron chelator directly inhibiting Fthl17f. Deferoxamine binds to ferric iron, forming a stable complex that prevents Fthl17f from binding and sequestering iron ions, potentially impacting its predicted function in intracellular iron sequestration within the cytoplasm of early conceptus cells. | ||||||
L-Mimosine | 500-44-7 | sc-201536A sc-201536B sc-201536 sc-201536C | 25 mg 100 mg 500 mg 1 g | $35.00 $86.00 $216.00 $427.00 | 8 | |
Iron-dependent enzyme inhibitor indirectly affecting Fthl17f. Mimosine inhibits iron-containing enzymes, potentially disrupting cellular processes that rely on these enzymes and indirectly influencing the predicted role of Fthl17f in iron binding and sequestration within the cytoplasm of early conceptus cells. | ||||||
Deferiprone | 30652-11-0 | sc-211220 sc-211220A | 1 g 5 g | $122.00 $131.00 | 5 | |
Iron chelator directly impacting Fthl17f. Deferiprone chelates iron ions, potentially interfering with the ferric and ferrous iron binding activities predicted for Fthl17f, and may disrupt its involvement in intracellular sequestration of iron ions within the cytoplasm of early conceptus cells. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
Thioredoxin-1 inhibitor indirectly influencing Fthl17f. PX-12 inhibits thioredoxin-1, a protein involved in redox regulation, potentially affecting the cellular redox environment and indirectly impacting the predicted function of Fthl17f in ferric and ferrous iron binding activities and intracellular sequestration within the cytoplasm of early conceptus cells. | ||||||
Triapine | 200933-27-3 | sc-475303 | 10 mg | $300.00 | ||
Ribonucleotide reductase inhibitor indirectly affecting Fthl17f. Triapine inhibits ribonucleotide reductase, an enzyme involved in DNA synthesis, potentially disrupting cellular processes and indirectly influencing the predicted role of Fthl17f in iron binding and sequestration within the cytoplasm of early conceptus cells. | ||||||
Gallium Nitrate | 69365-72-6 | sc-358673 sc-358673A | 1 g 5 g | $20.00 $80.00 | ||
Iron analog directly impacting Fthl17f. Gallium nitrate, structurally similar to iron, can replace iron in cellular processes, potentially interfering with the ferric and ferrous iron binding activities predicted for Fthl17f and disrupting its involvement in intracellular sequestration of iron ions within the cytoplasm of early conceptus cells. | ||||||
Lactoferrin | 146897-68-9 | sc-394420 sc-394420A sc-394420B sc-394420C | 10 mg 50 mg 100 mg 1 g | $120.00 $400.00 $569.00 $1465.00 | ||
Competitive inhibitor of iron binding to Fthl17f. Lactoferrin, an iron-binding glycoprotein, can compete with Fthl17f for binding to iron ions, potentially modulating its ability to sequester iron within the cytoplasm of early conceptus cells. | ||||||
L-Ascorbic acid, free acid | 50-81-7 | sc-202686 | 100 g | $45.00 | 5 | |
Enhancer of non-heme iron absorption indirectly influencing Fthl17f. Vitamin C enhances the absorption of non-heme iron, potentially increasing the availability of iron ions for Fthl17f binding and sequestration within the cytoplasm of early conceptus cells, indirectly affecting its predicted function in intracellular iron sequestration. | ||||||
apo-Transferrin | 11096-37-0 | sc-391092 sc-391092A sc-391092B | 100 mg 500 mg 1 g | $150.00 $469.00 $744.00 | 1 | |
Transferrin precursor indirectly affecting Fthl17f. Apotransferrin, the precursor of transferrin, may modulate cellular iron homeostasis and indirectly impact the predicted role of Fthl17f in ferric and ferrous iron binding activities and intracellular sequestration within the cytoplasm of early conceptus cells by influencing iron transport processes. | ||||||
Ferrostatin 1 | 347174-05-4 | sc-498126 sc-498126A | 10 mg 50 mg | $162.00 $442.00 | 15 | |
Ferroptosis inhibitor indirectly influencing Fthl17f. Ferrostatin-1 inhibits ferroptosis, a form of iron-dependent cell death, potentially altering cellular responses to iron levels and indirectly impacting the predicted function of Fthl17f in iron binding and sequestration within the cytoplasm of early conceptus cells. | ||||||